AU2001283740A1 - Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours - Google Patents
Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumoursInfo
- Publication number
- AU2001283740A1 AU2001283740A1 AU2001283740A AU8374001A AU2001283740A1 AU 2001283740 A1 AU2001283740 A1 AU 2001283740A1 AU 2001283740 A AU2001283740 A AU 2001283740A AU 8374001 A AU8374001 A AU 8374001A AU 2001283740 A1 AU2001283740 A1 AU 2001283740A1
- Authority
- AU
- Australia
- Prior art keywords
- methods
- chemotherapeutic agents
- treating neurological
- agents conjugated
- neurological tumours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 229940127089 cytotoxic agent Drugs 0.000 title 1
- 230000000926 neurological effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22625400P | 2000-08-17 | 2000-08-17 | |
| US60/226,254 | 2000-08-17 | ||
| PCT/CA2001/001158 WO2002013843A2 (en) | 2000-08-17 | 2001-08-17 | Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001283740A1 true AU2001283740A1 (en) | 2002-02-25 |
Family
ID=22848166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001283740A Abandoned AU2001283740A1 (en) | 2000-08-17 | 2001-08-17 | Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2001283740A1 (en) |
| WO (1) | WO2002013843A2 (en) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60234057D1 (en) | 2001-07-25 | 2009-11-26 | Raptor Pharmaceutical Inc | COMPOSITIONS AND METHODS FOR MODULATING TRANSPORT BY THE BLOOD-BRAIN BARRIER |
| US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
| US7125843B2 (en) | 2001-10-19 | 2006-10-24 | Neose Technologies, Inc. | Glycoconjugates including more than one peptide |
| US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| US7226903B2 (en) | 2001-10-10 | 2007-06-05 | Neose Technologies, Inc. | Interferon beta: remodeling and glycoconjugation of interferon beta |
| US7179617B2 (en) | 2001-10-10 | 2007-02-20 | Neose Technologies, Inc. | Factor IX: remolding and glycoconjugation of Factor IX |
| US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
| US7265084B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| US7696163B2 (en) | 2001-10-10 | 2010-04-13 | Novo Nordisk A/S | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| US7439043B2 (en) | 2001-10-10 | 2008-10-21 | Neose Technologies, Inc. | Galactosyl nucleotide sugars |
| IL161251A0 (en) | 2001-10-10 | 2004-09-27 | Neose Technologies Inc | Remodeling and glycoconjugation of peptides |
| US7265085B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycoconjugation methods and proteins/peptides produced by the methods |
| US7399613B2 (en) | 2001-10-10 | 2008-07-15 | Neose Technologies, Inc. | Sialic acid nucleotide sugars |
| US8008252B2 (en) | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
| US7297511B2 (en) | 2001-10-10 | 2007-11-20 | Neose Technologies, Inc. | Interferon alpha: remodeling and glycoconjugation of interferon alpha |
| US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
| US7473680B2 (en) | 2001-11-28 | 2009-01-06 | Neose Technologies, Inc. | Remodeling and glycoconjugation of peptides |
| US20050158296A1 (en) | 2002-01-11 | 2005-07-21 | Starr Christopher M. | Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes |
| EP1534823A4 (en) * | 2002-07-12 | 2008-12-31 | Biomarin Pharm Inc | USE OF ISOCYANATE BINDING AGENTS FOR PRODUCING BIOPOLYMER-HYDRAULIC ACTIVE SUBSTANCE CONJUGATES |
| CA2519092C (en) | 2003-03-14 | 2014-08-05 | Neose Technologies, Inc. | Branched water-soluble polymers and their conjugates |
| EP1613261A4 (en) | 2003-04-09 | 2011-01-26 | Novo Nordisk As | INTRACELLULAR FORMATION OF PEPTIDE CONJUGATES |
| EP1615945B1 (en) | 2003-04-09 | 2011-09-28 | BioGeneriX AG | Glycopegylation methods and proteins/peptides produced by the methods |
| US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
| ATE540055T1 (en) | 2003-05-09 | 2012-01-15 | Biogenerix Ag | COMPOSITIONS AND METHODS FOR PRODUCING HUMAN GROWTH HORMONE GLYCOSYLATION MUTANTS |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US20050026823A1 (en) | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
| EP1694347B1 (en) | 2003-11-24 | 2013-11-20 | BioGeneriX AG | Glycopegylated erythropoietin |
| US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
| US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| US7956032B2 (en) | 2003-12-03 | 2011-06-07 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
| US8361961B2 (en) | 2004-01-08 | 2013-01-29 | Biogenerix Ag | O-linked glycosylation of peptides |
| ATE465172T1 (en) | 2004-03-05 | 2010-05-15 | Univ Illinois | PEPTIDE CARRIER FOR DRUG ADMINISTRATION |
| RU2006138181A (en) | 2004-05-04 | 2008-06-10 | Ново Нордиск Хелс Кеа Аг (Ch) | O-RELATED Glycoforms of Polypeptides and a Method for Their Production |
| EP1771066A2 (en) | 2004-07-13 | 2007-04-11 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1 |
| US8268967B2 (en) | 2004-09-10 | 2012-09-18 | Novo Nordisk A/S | Glycopegylated interferon α |
| SI2586456T1 (en) | 2004-10-29 | 2016-05-31 | Ratiopharm Gmbh | Remodeling and glycopegylation of fibroblast growth factor (FGF) |
| NZ556436A (en) | 2005-01-10 | 2010-11-26 | Biogenerix Ag | Glycopegylated granulocyte colony stimulating factor |
| DE602006015929D1 (en) * | 2005-03-30 | 2010-09-16 | Saladax Biomedical Inc | DOXORUBICIN IMMUNE TEST |
| US9187546B2 (en) | 2005-04-08 | 2015-11-17 | Novo Nordisk A/S | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
| EP1888098A2 (en) | 2005-05-25 | 2008-02-20 | Neose Technologies, Inc. | Glycopegylated erythropoietin formulations |
| US20080255026A1 (en) | 2005-05-25 | 2008-10-16 | Glycopegylated Factor 1X | Glycopegylated Factor Ix |
| EP1745802A1 (en) * | 2005-07-20 | 2007-01-24 | Kreatech Biotechnology B.V. | Method of conjugating therapeutic compounds to cell targeting moieties via metal complexes |
| US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
| US20080242607A1 (en) | 2006-07-21 | 2008-10-02 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
| US20100075375A1 (en) | 2006-10-03 | 2010-03-25 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates |
| KR20100016160A (en) | 2007-04-03 | 2010-02-12 | 바이오제너릭스 에이지 | Methods of treatment using glycopegylated g-csf |
| JP5876649B2 (en) | 2007-06-12 | 2016-03-02 | ラツィオファルム ゲーエムベーハーratiopharm GmbH | Improved process for producing nucleotide sugars |
| US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
| CN101965200B (en) | 2008-02-27 | 2013-06-19 | 诺沃-诺迪斯克有限公司 | Conjugated factor VIII molecules |
| PL2717917T3 (en) | 2011-07-05 | 2016-12-30 | P97-antibody conjugates | |
| PT2739649T (en) | 2011-08-05 | 2018-01-03 | Bioasis Technologies Inc | P97 fragments with transfer activity |
| CN104662150B (en) | 2012-07-31 | 2018-07-10 | 比奥阿赛斯技术有限公司 | The lysosomal storage disease albumen and its application method of dephosphorylation |
| US9364567B2 (en) | 2013-03-13 | 2016-06-14 | Bioasis Technologies, Inc. | Fragments of p97 and uses thereof |
| RU2665688C2 (en) * | 2013-04-12 | 2018-09-04 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Dicarboxylic acid bisamide derivatives, their application, the pharmaceutical composition on their basis, methods for their production |
| WO2015117121A1 (en) | 2014-02-03 | 2015-08-06 | Bioasis Technologies, Inc. | P97 fusion proteins |
| CA2935805C (en) | 2014-02-19 | 2023-07-11 | Bioasis Technologies, Inc. | P97-ids fusion proteins |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2116979B (en) * | 1982-02-25 | 1985-05-15 | Ward Page Faulk | Conjugates of proteins with anti-tumour agents |
| US5137877B1 (en) * | 1990-05-14 | 1996-01-30 | Bristol Myers Squibb Co | Bifunctional linking compounds conjugates and methods for their production |
| DE4122210C2 (en) * | 1991-07-04 | 1999-04-01 | Deutsches Krebsforsch | Tumor-active compound-serum albumin conjugates, process for their preparation and their use |
| AU4553793A (en) * | 1992-07-10 | 1994-01-31 | University Of British Columbia, The | Use of p97 and iron binding proteins as diagnostic and therapeutic agents |
| US20040055022A1 (en) * | 2000-02-08 | 2004-03-18 | Nick Cheng | Compositions and methods for screening therapeutic agents |
-
2001
- 2001-08-17 AU AU2001283740A patent/AU2001283740A1/en not_active Abandoned
- 2001-08-17 WO PCT/CA2001/001158 patent/WO2002013843A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002013843A2 (en) | 2002-02-21 |
| WO2002013843A3 (en) | 2002-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001283740A1 (en) | Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours | |
| HUP0302352A3 (en) | Sn-38 lipid complexes and methods of use | |
| AU2001285020A1 (en) | P97-active agent conjugates and their methods of use | |
| AU7122801A (en) | New aporphine esters and their use in therapy | |
| AU2002221881A1 (en) | Carboxylic acid amide derivatives and their use in the treatment of thromboembolic diseases and tumours | |
| AU6492600A (en) | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs | |
| PL352330A1 (en) | Derivatives of pyridopyranoazepine, making of same and use of same in therapy | |
| AU2001283285A1 (en) | Antimicrobial composition and methods of use in the treatment of disease | |
| HUP0300848A3 (en) | A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer | |
| PL340604A1 (en) | Application of macrolydes in treating tumours and maculopathy | |
| PL357827A1 (en) | Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations | |
| AU2002243363A1 (en) | Use of aziridino-compounds in the treatment of immune dysfunctions | |
| IL136167A0 (en) | Conjugates useful in the treatment of prostate cancer | |
| AU6814601A (en) | Use of mutant herpes viruses and anticancer agents in the treatment of cancer | |
| AU5622401A (en) | Fabric treatment article and composition | |
| GB9928825D0 (en) | Improvements in and relating to grinding | |
| GB0031420D0 (en) | Improvements in and relating to methods of communication | |
| ZA9810974B (en) | Conjugates useful in the treatment of prostate cancer | |
| AU2001276462A1 (en) | Use of natural products in cancer treatment | |
| HUP0105351A3 (en) | Effervescent laxatives and their use | |
| AU1576501A (en) | Methods to enhance and confine gene expression in cancer therapy | |
| AU2001258575A1 (en) | Treatment of cancer and neurological diseases | |
| GB2348149B (en) | Improvements in and relating to games tables | |
| HU9900045D0 (en) | Improved leukaemic blood-based product and their use in therapy | |
| AU2021700A (en) | Methods of using temozolomide in the treatment of cancers |